Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Roberts

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Molecular Pharmacology|October 20, 2006
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatmentAdly Yacoub, William Hawkins, David Hanna, et al.
Psychosomatic Medicine|December 26, 2007
Depression and anxiety in adults with sickle cell disease: the PiSCES projectJames L Levenson, Donna K McClish, Bassam A Dahman, et al.
Journal of Opioid Management|May 20, 2015
Daily home opioid use in adults with sickle cell disease: The PiSCES projectWally R Smith, Donna K McClish, Bassam A Dahman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activationGuo Zhang, Margaret A Park, Clint Mitchell, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Leukemia & Lymphoma|December 28, 2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndromeBeata Holkova, Danielle Shafer, Victor Yazbeck, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Leukemia & Lymphoma|January 21, 2017
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphomaBeata Holkova, Victor Yazbeck, Maciej Kmieciak, et al.
Molecular Carcinogenesis|March 26, 2011
A novel role for the T-box transcription factor Tbx1 as a negative regulator of tumor cell growth in miceCarol S Trempus, Sung-Jen Wei, Margaret M Humble, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Molecular Pharmacology|October 20, 2006
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatmentAdly Yacoub, William Hawkins, David Hanna, et al.
Psychosomatic Medicine|December 26, 2007
Depression and anxiety in adults with sickle cell disease: the PiSCES projectJames L Levenson, Donna K McClish, Bassam A Dahman, et al.
Journal of Opioid Management|May 20, 2015
Daily home opioid use in adults with sickle cell disease: The PiSCES projectWally R Smith, Donna K McClish, Bassam A Dahman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activationGuo Zhang, Margaret A Park, Clint Mitchell, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Leukemia & Lymphoma|December 28, 2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndromeBeata Holkova, Danielle Shafer, Victor Yazbeck, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Leukemia & Lymphoma|January 21, 2017
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphomaBeata Holkova, Victor Yazbeck, Maciej Kmieciak, et al.
Molecular Carcinogenesis|March 26, 2011
A novel role for the T-box transcription factor Tbx1 as a negative regulator of tumor cell growth in miceCarol S Trempus, Sung-Jen Wei, Margaret M Humble, et al.
Pageof 11